Tatlisu Mustafa A, Kaya Adnan, Keskin Muhammed, Avsar Sahin, Bozbay Mehmet, Tatlisu Kiymet, Eren Mehmet
Department of Cardiovascular Science, Texas A&M Institute for Preclinical Science, College Station, TX, 77843, USA.
Department of Cardiology, Suruc State Hospital, Urfa, 63800, Turkey.
J Crit Care. 2017 Jun;39:248-253. doi: 10.1016/j.jcrc.2016.12.019. Epub 2016 Dec 29.
The aim of this study was to investigate the association of BUN levels with in-hospital and long-term adverse clinical outcomes in acute pulmonary embolism (APE) patients treated with tissue-plasminogen activator (t-PA).
This retrospective study included 252 consecutive confirmed APE patients treated with t-PA. An admission BUN of 34.5 mg/dL was identified through an ROC analysis as an optimal cutoff value to predict the in-hospital mortality with 85% sensitivity and 91% specificity (AUC: 0.91; 95% CI: 0.84-0.96; P<.001).
Our study showed that an increase in BUN levels was independently associated with a high risk of in-hospital all-cause mortality, low admission systolic blood pressure, use of inotropic drugs, and cardiogenic shock. In-hospital mortality rates were 51.1% in higher BUN group, and 1.9% in lower BUN group (P<.001).
In this study, elevated admission BUN level was found to be a predictor of all-cause in-hospital mortality. BUN testing is commonly part of the basic metabolic panel; and it can be used to detect high-risk patients with APE, and it bears little risk, is inexpensive, and easy to perform.
本研究旨在探讨在接受组织型纤溶酶原激活剂(t-PA)治疗的急性肺栓塞(APE)患者中,血尿素氮(BUN)水平与住院期间及长期不良临床结局之间的关联。
这项回顾性研究纳入了252例连续接受t-PA治疗的确诊APE患者。通过ROC分析确定,入院时BUN为34.5mg/dL是预测住院死亡率的最佳截断值,其灵敏度为85%,特异度为91%(AUC:0.91;95%CI:0.84-0.96;P<0.001)。
我们的研究表明,BUN水平升高与住院全因死亡率高风险、入院时收缩压低、使用血管活性药物及心源性休克独立相关。高BUN组的住院死亡率为51.1%,低BUN组为1.9%(P<0.001)。
在本研究中,发现入院时BUN水平升高是住院全因死亡率的一个预测指标。BUN检测通常是基本代谢指标的一部分;它可用于检测APE高危患者,且风险小、成本低且易于实施。